APA Citatie

Jaworski, J., Matucci-Cerinic, M., Schulze-Koops, H., Buch, M. H., Kucharz, E. J., Allanore, Y., . . . Babic, G. (2019). Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther.

Chicago Style citaat

Jaworski, Janusz, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Maya H. Buch, Eugeniusz J. Kucharz, Yannick Allanore, Arthur Kavanaugh, Philip Young, en Goran Babic. "Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-to-severe Rheumatoid Arthritis: 48-week Results From the Phase III, Randomized, Double-blind EQUIRA Study." Arthritis Res Ther 2019.

MLA citatie

Jaworski, Janusz, et al. "Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-to-severe Rheumatoid Arthritis: 48-week Results From the Phase III, Randomized, Double-blind EQUIRA Study." Arthritis Res Ther 2019.